Welcome to our dedicated page for Nakamoto SEC filings (Ticker: NAKAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for NAKAW on Stock Titan centers on the regulatory disclosures of Kindly MD, Inc. relating to its tradeable warrants to purchase common stock, which trade on the OTC Pink Market under the NAKAW symbol. These filings provide the primary source of information about the warrants and their context within the company’s capital structure.
Kindly MD, Inc.’s Form 8-K and Form 8-K/A describe several key matters: the identification of NAKAW as tradeable warrants to purchase shares of common stock, the company’s status as an emerging growth company, and its corporate details as a Utah corporation based in Salt Lake City, Utah. The filings also outline an Agreement and Plan of Merger under which Kindly Holdco Corp merged with and into Nakamoto Holdings Inc., with Nakamoto becoming a wholly owned subsidiary of Kindly MD, Inc.
These reports further discuss related financing arrangements, including a PIPE Transaction, the issuance of pre-funded warrants, and a Debt Transaction involving convertible debentures. In a separate Form 8-K, the company details a notice of redemption for a Secured Convertible Debenture, specifying that outstanding amounts not converted by the redemption date will be redeemed at 100% of principal plus a 1.5% payment premium.
On Stock Titan, users can review these filings as they are made available from EDGAR and use AI-powered summaries to understand the significance of items such as merger disclosures, supplemental risk factors, Management’s Discussion and Analysis, and the treatment of warrants and debentures. This helps clarify how NAKAW fits into Kindly MD, Inc.’s overall reporting and capital structure.
Kindly MD, Inc. discloses material risks and shareholder details in this S-3ASR filing. The company warns that costs and potential litigation related to a proposed Merger have been and will be incurred, that trading of its securities may be volatile, and that shareholders may face dilution from warrant exercises and future equity issuances. The filing highlights industry-specific regulatory risk for medical cannabis, competitive and technology threats, reliance on key management, and cybersecurity concerns. Significant beneficial ownership stakes are shown, including a holder with 133,928,571 shares (27.19%) and another with 114,246,002 shares (23.94%), and a large block totaling 53,571,429 shares (13.57%). The registrant describes permitted distribution methods for registered shares and undertakes post-effective filing obligations. The document includes officer and director signatures certifying the filing.
Kindly MD, Inc. filed an S-8 registration to register share awards under its employee plans. The filing references the Kindly MD, Inc. 2022 Equity Incentive Plan (incorporated by reference) and files the 2025 Equity Incentive Plan on Form S-8, includes corporate charter and bylaw exhibits, legal opinions and auditor consents, and standard indemnification terms for directors and officers.
Kindly MD, Inc. filed an amended Current Report (Form 8-K/A) that attaches exhibit-level disclosures for Nakamoto Holdings, Inc. The filing identifies the company's trading symbols as NAKA on The Nasdaq Stock Market LLC and NAKAW on the OTC Pink Market. It includes the consent of Wolf & Company, P.C., audited financial statements of Nakamoto as of April 30, 2025 and for the period from March 6, 2025 (inception) to April 30, 2025, unaudited financials as of June 30, 2025, unaudited pro forma condensed combined financial statements reflecting the acquisition of Nakamoto, supplemental risk factors, and management discussion and analysis for the stated periods. The filing is executed by CEO David Bailey.